Life Impact and Treatment Preferences of Individuals with Asthma and Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups

Advances in Therapy

Volumn 34, Issue 6, 2017, Pages 1466-1481

  Svedsater, Henrik ^a   Roberts, June ^b   Patel, Chloe ^c   Macey, Jake ^c   Hilton, Emma ^a   Bradshaw, Lisa ^d  

^a GLAXOSMITHKLINE   (United Kingdom)

^b SALFORD ROYAL NHS FOUNDATION TRUST   (United Kingdom)

^c ICON Clinical Research UK Ltd   (United Kingdom)

^d NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Asthma; Chronic obstructive pulmonary disease; Patient preference; Qualitative research; Quality of life; Respiratory

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; LONG ACTING DRUG; MUSCARINIC RECEPTOR BLOCKING AGENT; SHORT ACTING DRUG;

ADULT; ANXIETY DISORDER; ARTICLE; ASTHMA; BACKACHE; CHEST INFECTION; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COPING BEHAVIOR; COUGHING; DEPRESSION; DYSPNEA; FATIGUE; FEAR; FEMALE; HUMAN; INFORMATION PROCESSING; MAJOR CLINICAL STUDY; MALE; PANIC; PATIENT COMPLIANCE; PATIENT PARTICIPATION; PATIENT PREFERENCE; PATIENT SATISFACTION; QUALITY OF LIFE; RECURRENT DISEASE; SADNESS; SEMI STRUCTURED INTERVIEW; SLEEP DISORDER; STIGMA; TELEPHONE INTERVIEW; THORAX PAIN; WHEEZING; AGED; INTERVIEW; MENTAL HEALTH; MIDDLE AGED; PATHOPHYSIOLOGY; PSYCHOLOGY; SOCIAL STIGMA;

ADULT; AGED; ASTHMA; DEPRESSION; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MALE; MENTAL HEALTH; MIDDLE AGED; PATIENT SATISFACTION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SOCIAL STIGMA;

EID: 85019953761     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-017-0557-0     Document Type: Article

References (47)

1. Mukherjee M, Gupta R, Farr A, et al. Estimating the incidence, prevalence and true cost of asthma in the UK: secondary analysis of national stand-alone and linked databases in England, Northern Ireland, Scotland and Wales—a study protocol. BMJ Open. 2014;4:e006647.
2. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of COPD–2017. http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed 19 Jan 2017.
3. Asthma UK. Asthma facts and statistics: www.asthma.org.uk/asthma-facts-and-statistics. Accessed 07 Dec 2016.
4. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention, Global Initiative for Asthma–2015. http://www.ginasthma.org. Accessed 07 Dec 2016.
5. Fukuchi Y, Nishimura M, Ichinose M, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology. 2004;9:458–65.
6. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28:523–32.
7. Bergeson SC, Dean JD. A systems approach to patient-centered care. JAMA. 2006;296:2848–51.
8. Cooper V, Metcalf L, Versnel J, Upton J, Walker S, Horne R. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim Care Respir Med. 2015;25:15026.
9. Carranza Rosenzweig JR, Edwards L, Lincourt W, Dorinsky P, ZuWallack RL. The relationship between health-related quality of life, lung function and daily symptoms in patients with persistent asthma. Respir Med. 2004;98:1157–65.
10. Hughes M, Dunne M. The living with asthma study: issues affecting the perceived health and well-being of Irish adults with asthma. Ir J Med Sci. 2016;85:115–20.
11. Li HL, He XL, Liang BM, Zhang HP, Wang Y, Wang G. Anxiety but not depression symptoms are associated with greater perceived dyspnea in asthma during bronchoconstriction. Allergy Asthma Proc. 2015;36:447–57.
12. Price D, David-Wang A, Cho SH, et al. Time for a new language for asthma control: results from REALISE Asia. J Asthma Allergy. 2015;8:93–103.
13. Price D, Fletcher M, van der Molen T. Asthma control and management in 8,000 European patients: the REcognise Asthma and LInk to Symptoms and Experience (REALISE) survey. NPJ Prim Care Respir Med. 2014;24:14009.
14. Disler RT, Green A, Luckett T, et al. Experience of advanced chronic obstructive pulmonary disease: metasynthesis of qualitative research. J Pain Symptom Manag. 2014;48:1182–99.
15. Harrison SL, Apps L, Singh SJ, Steiner MC, Morgan MD, Robertson N. ‘Consumed by breathing’–a critical interpretive meta-synthesis of the qualitative literature. Chron Illn. 2014;10:31–49.
16. Cooney A, Mee L, Casey D, et al. Life with chronic obstructive pulmonary disease: striving for ‘controlled co-existence’. J Clin Nurs. 2013;22:986–95.
17. Philip J, Gold M, Brand C, Miller B, Douglass J, Sundararajan V. Facilitating change and adaptation: the experiences of current and bereaved carers of patients with severe chronic obstructive pulmonary disease. J Palliat Med. 2014;17:421–7.
18. Grant M, Cavanagh A, Yorke J. The impact of caring for those with chronic obstructive pulmonary disease (COPD) on carers’ psychological well-being: a narrative review. Int J Nurs Stud. 2012;49:1459–71.
19. Breekveldt-Postma NS, Koerselman J, Erkens JA, Lammers JW, Herings RM. Enhanced persistence with tiotropium compared with other respiratory drugs in COPD. Respir Med. 2007;101:1398–405.
20. Omenaas E, Svanes C, Janson C, et al. What can we learn about asthma and allergy from the follow-up of the RHINE and the ECRHS studies? Clin Respir J. 2008;2(Suppl 1):45–52.
21. Toy EL, Beaulieu NU, McHale JM, et al. Treatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costs. Respir Med. 2011;105:435–41.
22. Guest JF, Davie AM, Ruiz FJ, Greener MJ. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim Care Respir J. 2005;14:88–98.
23. Price D, Robertson A, Bullen K, Rand C, Horne R, Staudinger H. Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: a randomized open-label study. BMC Pulm Med. 2010;10:1.
24. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/. Accessed 15 May 2017.
25. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004;113:59–65.
26. Bayliss MS, Kosinski M, Turner-Bowker DM, Fortin E. Asthma Control Test™: a user’s guide. Lincoln: QualityMetric; 2003.
27. Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment Test (CAT™) scores. BMC Pulm Med. 2001;11:42.
28. GSK. COPD Assessment Test™ (CAT): expert guidance on frequently asked questions (user guide) 2012: www.catestonline.org/images/UserGuides/CATHCPUser%20guideEn.pdf. Accessed 7 Dec 2016.
29. Globe G, Martin M, Schatz M, et al. Symptoms and markers of symptom severity in asthma—content validity of the asthma symptom diary. Health Qual Life Outcomes. 2015;13:21.
30. Kulich K, Keininger DL, Tiplady B, Banerji D. Symptoms and impact of COPD assessed by an electronic diary in patients with moderate-to-severe COPD: psychometric results from the SHINE study. Int J Chron Obstr Pulm Dis. 2015;10:79–94.
31. Pisa G, Freytag S, Schandry R. Chronic obstructive pulmonary disease (COPD) patients’ disease-related preferences: a study using conjoint analysis. Patient. 2013;6:93–101.
32. Feldman JM, Lehrer PM, Borson S, Hallstrand TS, Siddique MI. Health care use and quality of life among patients with asthma and panic disorder. J Asthma. 2005;42:179–84.
33. Matte DL, Pizzichini MM, Hoepers AT, et al. Prevalence of depression in COPD: a systematic review and meta-analysis of controlled studies. Respir Med. 2016;117:154–61.
34. Bårnes CB, Ulrik CS. Asthma and adherence to inhaled corticosteroids: current status and future perspectives. Respir Care. 2015;60:455–68.
35. Milgrom H, Bender B, Ackerson L, Bowry P, Smith B, Rand C. Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol. 1996;98(6 Pt 1):1051–7.
36. Bender B, Wamboldt FS, O’Connor SL, et al. Measurement of children’s asthma medication adherence by self report, mother report, canister weight, and Doser CT. Ann Allergy Asthma Immunol. 2000;85:416–21.
37. Nelson E, Conger B, Douglass R, et al. Functional health status levels of primary care patients. JAMA. 1983;249:3331–8.
38. Mapel DW, Dalal AA, Johnson PT, Becker LK, Hunter AG. Application of the new GOLD COPD staging system to a US primary care cohort, with comparison to physician and patient impressions of severity. Int J Chron Obstr Pulm Dis. 2015;10:1477–86.
39. Miravitlles M, Worth H, Soler Cataluña JJ, et al. Observational study to characterise 24-hour COPD symptoms and their relationship with patient-reported outcomes: results from the ASSESS study. Respir Res. 2014;15:122.
40. Price D, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of night-time symptoms in COPD: a real-world study in five European countries. Int J Chron Obstr Pulm Dis. 2013;8:595–603.
41. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3:77–101.
42. Kerr C, Nixon A, Angalakuditi M. The impact of epilepsy on children and adult patients’ lives: development of a conceptual model from qualitative literature. Seizure. 2011;20:764–74.
43. Reddel HK, Sawyer SM, Everett PW, Flood PV, Peters MJ. Asthma control in Australia: a cross-sectional web-based survey in a nationally representative population. Med J Aust. 2015;202:492–7.
44. Wells KE, Cajigal S, Peterson EL, et al. Assessing differences in inhaled corticosteroid response by self-reported race-ethnicity and genetic ancestry among asthmatic subjects. J Allergy Clin Immunol. 2016;137:1364–9.
45. Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. N Engl J Med. 2016;375:1253–60.
46. Legro RS, Chen G, Kunselman AR, et al. Smoking in infertile women with polycystic ovary syndrome: baseline validation of self-report and effects on phenotype. Hum Reprod. 2014;29:2680–6.
47. Morales NA, Romano MA, Cummings MK, et al. Accuracy of self-reported tobacco use in newly diagnosed cancer patients. Cancer Causes Control. 2013;24:1223–30.